Intrahepatic Cholestasis of Pregnancy: A Systematic Review of Diagnostic Approaches, Evidence-Based Management Algorithms, Maternal–Fetal Outcomes, and Emerging Therapeutic Directions

Aim: To summarize current evidence on the diagnosis and management of intrahepatic cholestasis of pregnancy (ICP), focusing on diagnostic biomarkers, pharmacological treatment, fetal surveillance, delivery planning, maternal–fetal outcomes, and emerging therapeutic approaches. Materials and Methods: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Scopus, Web of Science, and SinoMed (Chinese Biomedical Literature Service System), were searched for relevant publications published between January 2016 and September 2026. Forty studies meeting the eligibility criteria were included in the final qualitative synthesis. The evidence was evaluated across diagnostic biomarkers, pharmacological interventions, fetal surveillance, delivery planning, and emerging therapeutic approaches. Results: Serum total bile acid concentrations remain central to the diagnosis and risk stratification of ICP, while maternal clinical characteristics, liver function tests, and gestational age at onset contribute to the overall assessment. Ursodeoxycholic acid (UDCA) remains the principal pharmacological treatment for maternal symptoms and biochemical abnormalities; however, evidence for its effect on major adverse perinatal outcomes remains limited. Maternal–fetal risk assessment, serial evaluation of bile acid concentrations, individualized fetal surveillance, and appropriately timed delivery are essential components of management. Emerging approaches include improved biomarker-based risk stratification and the investigation of alternative therapeutic targets. Conclusion: The management of ICP requires an individualized, risk-based approach integrating biochemical assessment, maternal symptom control, and gestational-age-specific obstetric planning. Serum bile acid concentrations remain central to evaluating fetal risk and guiding clinical decisions. Further prospective studies are needed to validate emerging biomarkers, establish the comparative effectiveness of therapeutic strategies, and refine management algorithms to improve maternal and perinatal outcomes.

Authors

Institutions

Publication Details

Journal
Fetal Medicine Obstetrics and Gynecology
Published
2026-11-21
DOI
https://doi.org/10.70926/fmog/1/2026.3.1.0001.cho
Primary Topic
Pregnancy and preeclampsia studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intrahepatic Cholestasis of Pregnancy: A Systematic Review of Diagnostic Approaches, Evidence-Based Management Algorithms, Maternal–Fetal Outcomes, and Emerging Therapeutic Directions

Petar N. Ignatov, Zlatko Kirovakov, Boris Stoilov, Teodora Kirovakova
Fetal Medicine Obstetrics and Gynecology
Pregnancy and preeclampsia studies
article

Intrahepatic Cholestasis of Pregnancy: A Systematic Review of Diagnostic Approaches, Evidence-Based Management Algorithms, Maternal–Fetal Outcomes, and Emerging Therapeutic Directions

Petar N. Ignatov, Zlatko Kirovakov, Boris Stoilov, Teodora Kirovakova
article en

Abstract

Aim: To summarize current evidence on the diagnosis and management of intrahepatic cholestasis of pregnancy (ICP), focusing on diagnostic biomarkers, pharmacological treatment, fetal surveillance, delivery planning, maternal–fetal outcomes, and emerging therapeutic approaches. Materials and Methods: A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Scopus, Web of Science, and SinoMed (Chinese Biomedical Literature Service System), were searched for relevant publications published between January 2016 and September 2026. Forty studies meeting the eligibility criteria were included in the final qualitative synthesis. The evidence was evaluated across diagnostic biomarkers, pharmacological interventions, fetal surveillance, delivery planning, and emerging therapeutic approaches. Results: Serum total bile acid concentrations remain central to the diagnosis and risk stratification of ICP, while maternal clinical characteristics, liver function tests, and gestational age at onset contribute to the overall assessment. Ursodeoxycholic acid (UDCA) remains the principal pharmacological treatment for maternal symptoms and biochemical abnormalities; however, evidence for its effect on major adverse perinatal outcomes remains limited. Maternal–fetal risk assessment, serial evaluation of bile acid concentrations, individualized fetal surveillance, and appropriately timed delivery are essential components of management. Emerging approaches include improved biomarker-based risk stratification and the investigation of alternative therapeutic targets. Conclusion: The management of ICP requires an individualized, risk-based approach integrating biochemical assessment, maternal symptom control, and gestational-age-specific obstetric planning. Serum bile acid concentrations remain central to evaluating fetal risk and guiding clinical decisions. Further prospective studies are needed to validate emerging biomarkers, establish the comparative effectiveness of therapeutic strategies, and refine management algorithms to improve maternal and perinatal outcomes.

Fetal Medicine Obstetrics and GynecologyVol. 3(1)
Medical University Plovdiv (BG), Medical University of Sofia (BG), Prof. Assen Zlatarov University (BG)
Pregnancy and preeclampsia studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon